Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms
The effect of statin therapy on plasma adiponectin levels has not been conclusively studied. Therefore, we aimed to evaluate this effect through a systematic review and meta-analysis of available randomized controlled trials (RCTs). Quantitative data synthesis was performed using a random-effects mo...
Saved in:
| Published in: | Atherosclerosis Vol. 253; pp. 194 - 208 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Ireland
Elsevier B.V
01.10.2016
|
| Subjects: | |
| ISSN: | 0021-9150, 1879-1484, 1879-1484 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The effect of statin therapy on plasma adiponectin levels has not been conclusively studied. Therefore, we aimed to evaluate this effect through a systematic review and meta-analysis of available randomized controlled trials (RCTs).
Quantitative data synthesis was performed using a random-effects model with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics.
In 30 studies (43 study arms) with 2953 participants, a significant increase in plasma adiponectin levels was observed after statin therapy (WMD: 0.57 μg/mL, 95% CI: 0.18, 0.95, p = 0.004). In subgroup analysis, atorvastatin, simvastatin, rosuvastatin, pravastatin and pitavastatin were found to change plasma adiponectin concentrations by 0.70 μg/mL (95% CI: −0.26, 1.65), 0.50 μg/mL (95% CI: −0.44, 1.45), −0.70 μg/mL (95% CI: −1.08, −0.33), 0.62 μg/mL (95% CI: −0.12, 1.35), and 0.51 μg/mL (95% CI: 0.30, 0.72), respectively. With respect to duration of treatment, there was a significant increase in the subset of trials lasting ≥12 weeks (WMD: 0.88 μg/mL, 95% CI: 0.19, 1.57, p = 0.012) but not in the subset of <12 weeks of duration (WMD: 0.18 μg/mL, 95% CI: −0.23, 0.58, p = 0.390). Random-effects meta-regression suggested a significant association between statin-induced elevation of plasma adiponectin and changes in plasma low density lipoprotein cholesterol levels (slope: 0.04; 95% CI: 0.01, 0.06; p = 0.002).
The meta-analysis showed a significant increase in plasma adiponectin levels following statin therapy. Although statins are known to increase the risk for new onset diabetes mellitus, our data might suggest that the mechanism for this is unlikely to be due to a reduction in adiponectin expression.
[Display omitted]
•The effect of statin therapy on plasma adiponectin levels has not been conclusively studied.•The analysis shows a significant increase in plasma adiponectin levels after statin therapy (WMD: +0.57 μg/mL).•The meta-analysis confirmed that statins may have an important impact on the adiponectin levels.•The pleiotropic adiponectin-elevating effect of statins might explain the benefits of statins in reducing the CV risk. |
|---|---|
| AbstractList | The effect of statin therapy on plasma adiponectin levels has not been conclusively studied. Therefore, we aimed to evaluate this effect through a systematic review and meta-analysis of available randomized controlled trials (RCTs).
Quantitative data synthesis was performed using a random-effects model with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics.
In 30 studies (43 study arms) with 2953 participants, a significant increase in plasma adiponectin levels was observed after statin therapy (WMD: 0.57 μg/mL, 95% CI: 0.18, 0.95, p = 0.004). In subgroup analysis, atorvastatin, simvastatin, rosuvastatin, pravastatin and pitavastatin were found to change plasma adiponectin concentrations by 0.70 μg/mL (95% CI: −0.26, 1.65), 0.50 μg/mL (95% CI: −0.44, 1.45), −0.70 μg/mL (95% CI: −1.08, −0.33), 0.62 μg/mL (95% CI: −0.12, 1.35), and 0.51 μg/mL (95% CI: 0.30, 0.72), respectively. With respect to duration of treatment, there was a significant increase in the subset of trials lasting ≥12 weeks (WMD: 0.88 μg/mL, 95% CI: 0.19, 1.57, p = 0.012) but not in the subset of <12 weeks of duration (WMD: 0.18 μg/mL, 95% CI: −0.23, 0.58, p = 0.390). Random-effects meta-regression suggested a significant association between statin-induced elevation of plasma adiponectin and changes in plasma low density lipoprotein cholesterol levels (slope: 0.04; 95% CI: 0.01, 0.06; p = 0.002).
The meta-analysis showed a significant increase in plasma adiponectin levels following statin therapy. Although statins are known to increase the risk for new onset diabetes mellitus, our data might suggest that the mechanism for this is unlikely to be due to a reduction in adiponectin expression.
[Display omitted]
•The effect of statin therapy on plasma adiponectin levels has not been conclusively studied.•The analysis shows a significant increase in plasma adiponectin levels after statin therapy (WMD: +0.57 μg/mL).•The meta-analysis confirmed that statins may have an important impact on the adiponectin levels.•The pleiotropic adiponectin-elevating effect of statins might explain the benefits of statins in reducing the CV risk. The effect of statin therapy on plasma adiponectin levels has not been conclusively studied. Therefore, we aimed to evaluate this effect through a systematic review and meta-analysis of available randomized controlled trials (RCTs). Quantitative data synthesis was performed using a random-effects model with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics. In 30 studies (43 study arms) with 2953 participants, a significant increase in plasma adiponectin levels was observed after statin therapy (WMD: 0.57 μg/mL, 95% CI: 0.18, 0.95, p = 0.004). In subgroup analysis, atorvastatin, simvastatin, rosuvastatin, pravastatin and pitavastatin were found to change plasma adiponectin concentrations by 0.70 μg/mL (95% CI: -0.26, 1.65), 0.50 μg/mL (95% CI: -0.44, 1.45), -0.70 μg/mL (95% CI: -1.08, -0.33), 0.62 μg/mL (95% CI: -0.12, 1.35), and 0.51 μg/mL (95% CI: 0.30, 0.72), respectively. With respect to duration of treatment, there was a significant increase in the subset of trials lasting ≥12 weeks (WMD: 0.88 μg/mL, 95% CI: 0.19, 1.57, p = 0.012) but not in the subset of <12 weeks of duration (WMD: 0.18 μg/mL, 95% CI: -0.23, 0.58, p = 0.390). Random-effects meta-regression suggested a significant association between statin-induced elevation of plasma adiponectin and changes in plasma low density lipoprotein cholesterol levels (slope: 0.04; 95% CI: 0.01, 0.06; p = 0.002). The meta-analysis showed a significant increase in plasma adiponectin levels following statin therapy. Although statins are known to increase the risk for new onset diabetes mellitus, our data might suggest that the mechanism for this is unlikely to be due to a reduction in adiponectin expression. Abstract Background and aims The effect of statin therapy on plasma adiponectin levels has not been conclusively studied. Therefore, we aimed to evaluate this effect through a systematic review and meta-analysis of available randomized controlled trials (RCTs). Methods Quantitative data synthesis was performed using a random-effects model with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics. Results In 30 studies (43 study arms) with 2953 participants, a significant increase in plasma adiponectin levels was observed after statin therapy (WMD: 0.57 μg/mL, 95% CI: 0.18, 0.95, p = 0.004). In subgroup analysis, atorvastatin, simvastatin, rosuvastatin, pravastatin and pitavastatin were found to change plasma adiponectin concentrations by 0.70 μg/mL (95% CI: −0.26, 1.65), 0.50 μg/mL (95% CI: −0.44, 1.45), −0.70 μg/mL (95% CI: −1.08, −0.33), 0.62 μg/mL (95% CI: −0.12, 1.35), and 0.51 μg/mL (95% CI: 0.30, 0.72), respectively. With respect to duration of treatment, there was a significant increase in the subset of trials lasting ≥12 weeks (WMD: 0.88 μg/mL, 95% CI: 0.19, 1.57, p = 0.012) but not in the subset of <12 weeks of duration (WMD: 0.18 μg/mL, 95% CI: −0.23, 0.58, p = 0.390). Random-effects meta-regression suggested a significant association between statin-induced elevation of plasma adiponectin and changes in plasma low density lipoprotein cholesterol levels (slope: 0.04; 95% CI: 0.01, 0.06; p = 0.002). Conclusions The meta-analysis showed a significant increase in plasma adiponectin levels following statin therapy. Although statins are known to increase the risk for new onset diabetes mellitus, our data might suggest that the mechanism for this is unlikely to be due to a reduction in adiponectin expression. The effect of statin therapy on plasma adiponectin levels has not been conclusively studied. Therefore, we aimed to evaluate this effect through a systematic review and meta-analysis of available randomized controlled trials (RCTs).BACKGROUND AND AIMSThe effect of statin therapy on plasma adiponectin levels has not been conclusively studied. Therefore, we aimed to evaluate this effect through a systematic review and meta-analysis of available randomized controlled trials (RCTs).Quantitative data synthesis was performed using a random-effects model with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics.METHODSQuantitative data synthesis was performed using a random-effects model with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics.In 30 studies (43 study arms) with 2953 participants, a significant increase in plasma adiponectin levels was observed after statin therapy (WMD: 0.57 μg/mL, 95% CI: 0.18, 0.95, p = 0.004). In subgroup analysis, atorvastatin, simvastatin, rosuvastatin, pravastatin and pitavastatin were found to change plasma adiponectin concentrations by 0.70 μg/mL (95% CI: -0.26, 1.65), 0.50 μg/mL (95% CI: -0.44, 1.45), -0.70 μg/mL (95% CI: -1.08, -0.33), 0.62 μg/mL (95% CI: -0.12, 1.35), and 0.51 μg/mL (95% CI: 0.30, 0.72), respectively. With respect to duration of treatment, there was a significant increase in the subset of trials lasting ≥12 weeks (WMD: 0.88 μg/mL, 95% CI: 0.19, 1.57, p = 0.012) but not in the subset of <12 weeks of duration (WMD: 0.18 μg/mL, 95% CI: -0.23, 0.58, p = 0.390). Random-effects meta-regression suggested a significant association between statin-induced elevation of plasma adiponectin and changes in plasma low density lipoprotein cholesterol levels (slope: 0.04; 95% CI: 0.01, 0.06; p = 0.002).RESULTSIn 30 studies (43 study arms) with 2953 participants, a significant increase in plasma adiponectin levels was observed after statin therapy (WMD: 0.57 μg/mL, 95% CI: 0.18, 0.95, p = 0.004). In subgroup analysis, atorvastatin, simvastatin, rosuvastatin, pravastatin and pitavastatin were found to change plasma adiponectin concentrations by 0.70 μg/mL (95% CI: -0.26, 1.65), 0.50 μg/mL (95% CI: -0.44, 1.45), -0.70 μg/mL (95% CI: -1.08, -0.33), 0.62 μg/mL (95% CI: -0.12, 1.35), and 0.51 μg/mL (95% CI: 0.30, 0.72), respectively. With respect to duration of treatment, there was a significant increase in the subset of trials lasting ≥12 weeks (WMD: 0.88 μg/mL, 95% CI: 0.19, 1.57, p = 0.012) but not in the subset of <12 weeks of duration (WMD: 0.18 μg/mL, 95% CI: -0.23, 0.58, p = 0.390). Random-effects meta-regression suggested a significant association between statin-induced elevation of plasma adiponectin and changes in plasma low density lipoprotein cholesterol levels (slope: 0.04; 95% CI: 0.01, 0.06; p = 0.002).The meta-analysis showed a significant increase in plasma adiponectin levels following statin therapy. Although statins are known to increase the risk for new onset diabetes mellitus, our data might suggest that the mechanism for this is unlikely to be due to a reduction in adiponectin expression.CONCLUSIONSThe meta-analysis showed a significant increase in plasma adiponectin levels following statin therapy. Although statins are known to increase the risk for new onset diabetes mellitus, our data might suggest that the mechanism for this is unlikely to be due to a reduction in adiponectin expression. |
| Author | Toth, Peter P. Rysz, Jacek Blaha, Michael J. Banach, Maciej Sahebkar, Amirhossein Rembek-Wieliczko, Magdalena Pencina, Michael J. Martin, Seth S. Lip, Gregory Y.H. Chruściel, Piotr Ursoniu, Sorin Jones, Steven R. Mosteoru, Svetlana Serban, Maria-Corina Ray, Kausik K. Mikhailidis, Dimitri P. |
| Author_xml | – sequence: 1 givenname: Piotr surname: Chruściel fullname: Chruściel, Piotr organization: Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland – sequence: 2 givenname: Amirhossein surname: Sahebkar fullname: Sahebkar, Amirhossein organization: Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran – sequence: 3 givenname: Magdalena surname: Rembek-Wieliczko fullname: Rembek-Wieliczko, Magdalena organization: Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland – sequence: 4 givenname: Maria-Corina surname: Serban fullname: Serban, Maria-Corina organization: Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA – sequence: 5 givenname: Sorin surname: Ursoniu fullname: Ursoniu, Sorin organization: Department of Functional Sciences, Discipline of Public Health, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania – sequence: 6 givenname: Dimitri P. surname: Mikhailidis fullname: Mikhailidis, Dimitri P. organization: Department of Clinical Biochemistry, Royal Free Campus, University College London Medical School, University College London (UCL), London, UK – sequence: 7 givenname: Steven R. surname: Jones fullname: Jones, Steven R. organization: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA – sequence: 8 givenname: Svetlana surname: Mosteoru fullname: Mosteoru, Svetlana organization: Institute for Cardiovascular Medicine Timisoara, Cardiology Department, University of Medicine and Pharmacy “Victor Babes”, Timisoara, Romania – sequence: 9 givenname: Michael J. surname: Blaha fullname: Blaha, Michael J. organization: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA – sequence: 10 givenname: Seth S. surname: Martin fullname: Martin, Seth S. organization: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA – sequence: 11 givenname: Jacek surname: Rysz fullname: Rysz, Jacek organization: Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland – sequence: 12 givenname: Peter P. surname: Toth fullname: Toth, Peter P. organization: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA – sequence: 13 givenname: Gregory Y.H. surname: Lip fullname: Lip, Gregory Y.H. organization: University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK – sequence: 14 givenname: Michael J. surname: Pencina fullname: Pencina, Michael J. organization: Duke Clinical Research Institute, Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA – sequence: 15 givenname: Kausik K. surname: Ray fullname: Ray, Kausik K. organization: Department of Primary Care and Public Health, School of Public Health, Imperial College London, UK – sequence: 16 givenname: Maciej orcidid: 0000-0001-6690-6874 surname: Banach fullname: Banach, Maciej email: maciejbanach@aol.co.uk organization: Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27498397$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVkt1qFTEUhYNU7Gn1FSQ3gjczJvOXRFAoh7YWCl6o1yGT2YM5ZpIxyVHGV_Clm-mpXhwQ6k1-1_7YWStn6MR5Bwi9oqSkhHZvdqVKXyH4qO06mlhW-bgkrOSCPUEbypkoaMObE7QhpKKFoC05RWcx7gghDaP8GTqtWCN4LdgG_b6ZZqUT9iOOSSXj8EpX84K9w7NVcVJYDWbOTej1VnunwaWQpd7Ft_gCxyUmmPJe4wA_DPzEyg14gqQK5ZRdcosrvalxyBd-Mr9gWDEpeGvzMgWjLFZhis_R01HZCC8e5nP05ery8_ZDcfvx-mZ7cVvormKpqDtogbOu16omuoaK6raruooqQjltWE9EPXQCWN9WqgdNGG9HMoiR1j3X-d3n6PWBOwf_fQ8xyclEDdYqB34fJeV1W7ciM7P05YN0308wyDmYSYVF_jEwC94dBDqHEQOMfyWUyDUwuZNHgck1MEmY5Pf126N6bdK9udljYx9NuT5QINuWMwgyagM5qcGEnJscvHk06f0RSVvjjFb2GywQd34fcqjZIxkrSeSn9YutP4x2NaWCNxlw-W_AfzRyB13E75M |
| CitedBy_id | crossref_primary_10_1002_jcp_26040 crossref_primary_10_1016_j_phrs_2018_06_020 crossref_primary_10_1016_j_heliyon_2024_e28837 crossref_primary_10_1007_s00580_018_2652_2 crossref_primary_10_1016_j_metabol_2018_08_003 crossref_primary_10_3390_jcm11082250 crossref_primary_10_1080_14622416_2025_2558499 crossref_primary_10_1016_j_tifs_2020_03_026 crossref_primary_10_1016_j_pharmthera_2020_107483 crossref_primary_10_2174_0113816128285148240122112045 crossref_primary_10_1002_jcsm_12654 crossref_primary_10_1007_s43440_023_00553_6 crossref_primary_10_1186_s12944_019_1139_8 crossref_primary_10_1016_j_phrs_2019_104469 crossref_primary_10_1007_s00011_022_01615_w crossref_primary_10_1111_eci_13388 crossref_primary_10_1002_biof_1597 crossref_primary_10_1016_j_biocel_2020_105735 crossref_primary_10_1016_j_drudis_2019_04_007 crossref_primary_10_15829_1728_8800_2022_3496 crossref_primary_10_3390_jcm8091413 crossref_primary_10_1007_s12016_020_08791_9 crossref_primary_10_1161_STROKEAHA_119_026280 crossref_primary_10_1007_s43440_024_00582_9 crossref_primary_10_1016_j_preghy_2020_11_014 crossref_primary_10_2174_0929867330666230308121645 crossref_primary_10_1080_17520363_2025_2521253 crossref_primary_10_1016_j_plipres_2021_101127 crossref_primary_10_1371_journal_pone_0305863 crossref_primary_10_1136_bmjopen_2017_015935 crossref_primary_10_1186_s12933_020_01096_3 crossref_primary_10_1007_s11255_021_02828_4 crossref_primary_10_1016_j_jksus_2022_102347 crossref_primary_10_1186_s12944_019_1172_7 crossref_primary_10_2174_0109298673264305231025093939 crossref_primary_10_1016_j_prp_2025_155931 crossref_primary_10_1016_j_greeac_2024_100100 crossref_primary_10_1016_j_biopha_2020_110311 crossref_primary_10_1186_s12967_020_02326_8 crossref_primary_10_2174_1389450121666200302095103 crossref_primary_10_1016_j_procbio_2022_12_034 crossref_primary_10_2174_0929867327666200427092114 crossref_primary_10_1155_2022_8732360 crossref_primary_10_1016_j_metabol_2020_154375 crossref_primary_10_1177_20420188231222371 crossref_primary_10_1186_s13065_023_01040_y crossref_primary_10_1016_j_erss_2017_12_005 crossref_primary_10_1002_jcp_31200 crossref_primary_10_1016_j_prp_2024_155589 crossref_primary_10_1080_10408398_2017_1366892 crossref_primary_10_3389_fendo_2019_00842 crossref_primary_10_1002_jcp_27121 crossref_primary_10_1016_j_humgen_2025_201456 crossref_primary_10_1016_j_phrs_2019_104289 crossref_primary_10_1097_MOL_0000000000000431 crossref_primary_10_1210_js_2018_00033 crossref_primary_10_1007_s11154_025_09980_7 crossref_primary_10_1016_j_lfs_2020_117682 crossref_primary_10_14341_omet9765 crossref_primary_10_1007_s10741_020_09929_9 crossref_primary_10_1016_j_bmcl_2024_129762 crossref_primary_10_1016_j_ijcard_2018_03_132 crossref_primary_10_1002_jcb_27761 crossref_primary_10_1111_bph_13650 crossref_primary_10_1016_j_phrs_2018_08_014 crossref_primary_10_1186_s12950_024_00421_x crossref_primary_10_1186_s12933_021_01411_6 crossref_primary_10_1016_j_jvssci_2021_04_001 crossref_primary_10_1097_HCO_0000000000000397 crossref_primary_10_1002_biof_1684 crossref_primary_10_1002_jcsm_12579 crossref_primary_10_1080_09513590_2018_1481944 crossref_primary_10_1007_s12170_016_0523_4 crossref_primary_10_3390_jcm11051313 crossref_primary_10_1016_j_prp_2025_156005 crossref_primary_10_1016_j_drudis_2017_09_014 crossref_primary_10_1515_revneuro_2023_0005 crossref_primary_10_1007_s40265_021_01510_4 crossref_primary_10_1016_j_ejim_2020_04_005 crossref_primary_10_1038_s41598_017_07355_w crossref_primary_10_1016_j_plipres_2020_101054 crossref_primary_10_1007_s11883_020_00837_9 crossref_primary_10_1016_j_artere_2019_10_003 crossref_primary_10_1016_j_cyto_2021_155698 crossref_primary_10_1055_a_1699_2380 crossref_primary_10_1016_j_semcancer_2020_08_002 crossref_primary_10_3390_jcm11226756 crossref_primary_10_3390_diagnostics11101774 crossref_primary_10_3389_fendo_2022_814209 crossref_primary_10_1016_j_ejphar_2020_173745 crossref_primary_10_1111_bph_70131 crossref_primary_10_1080_00325481_2017_1292107 crossref_primary_10_1016_j_pharmthera_2020_107614 crossref_primary_10_1186_s12950_024_00420_y crossref_primary_10_1016_j_atherosclerosis_2016_08_009 crossref_primary_10_3390_ijms23169326 crossref_primary_10_3390_ijms20051190 crossref_primary_10_3803_EnM_2018_33_1_33 crossref_primary_10_1186_s12879_020_05594_3 crossref_primary_10_1007_s43440_025_00694_w crossref_primary_10_1007_s10787_019_00653_x crossref_primary_10_1016_j_metabol_2019_153953 crossref_primary_10_1016_j_atherosclerosis_2025_119235 crossref_primary_10_17816_CS676903 crossref_primary_10_1016_j_prp_2024_155258 crossref_primary_10_1111_eci_13454 crossref_primary_10_1002_jcp_28123 crossref_primary_10_1016_j_ejmech_2025_117816 crossref_primary_10_2174_0109298673245069231010065055 crossref_primary_10_1007_s43440_024_00678_2 crossref_primary_10_1016_j_jacl_2017_10_011 crossref_primary_10_1007_s12026_025_09653_2 crossref_primary_10_3390_jcm8122051 crossref_primary_10_1016_j_sajb_2025_08_017 crossref_primary_10_3390_ijms232314982 crossref_primary_10_1210_endrev_bnae021 crossref_primary_10_1016_j_arr_2020_101024 crossref_primary_10_1155_2022_3577761 crossref_primary_10_1177_0003319716688301 crossref_primary_10_7759_cureus_44411 crossref_primary_10_1093_jac_dkab158 crossref_primary_10_1016_j_intimp_2019_05_006 crossref_primary_10_1002_iub_2073 crossref_primary_10_1080_13543784_2017_1280458 crossref_primary_10_1016_j_biopha_2018_03_003 crossref_primary_10_1016_j_ejphar_2025_177491 crossref_primary_10_1002_jcp_28134 crossref_primary_10_1016_j_molmet_2020_101049 crossref_primary_10_3390_biom9040118 crossref_primary_10_1097_MD_0000000000014878 crossref_primary_10_1186_s12933_022_01524_6 crossref_primary_10_1186_s12944_024_02151_8 crossref_primary_10_1007_s10067_018_4258_0 crossref_primary_10_1016_j_biopha_2020_111179 crossref_primary_10_1016_j_chest_2019_10_011 crossref_primary_10_1097_MCG_0000000000000956 crossref_primary_10_3390_life12050760 crossref_primary_10_1177_2047487319862907 crossref_primary_10_1016_j_numecd_2021_03_021 crossref_primary_10_15829_1560_4071_2024_6148 crossref_primary_10_1016_j_cellsig_2024_111213 |
| Cites_doi | 10.1016/j.atherosclerosis.2010.08.056 10.1186/1471-2288-5-13 10.2169/internalmedicine.47.1159 10.1016/j.atherosclerosis.2008.09.021 10.2337/diacare.27.10.2450 10.1016/j.phrs.2015.07.008 10.1177/1479164109339966 10.1177/2040622315596118 10.1124/pr.111.004994 10.1111/j.1472-8206.2010.00847.x 10.1185/03007995.2013.874989 10.1177/1535370213517614 10.2337/dc07-2199 10.1111/j.1476-5381.2011.01395.x 10.1016/j.metabol.2005.02.011 10.1016/j.ijcard.2010.10.103 10.1185/03007990802596813 10.3390/ijms15046184 10.1016/j.nut.2015.01.010 10.1016/j.mce.2015.04.015 10.1155/2014/658913 10.1111/j.0006-341X.2000.00455.x 10.1177/0003319713485807 10.5114/aoms.2012.29518 10.1016/j.amjcard.2007.06.028 10.1161/01.CIR.0000143085.86697.13 10.1016/j.lfs.2015.03.010 10.1080/09537100802409921 10.2337/diabetes.51.1.37 10.1002/clc.20181 10.1016/S0014-5793(01)03007-1 10.1016/j.metabol.2012.02.005 10.1038/srep09902 10.1016/j.atherosclerosis.2006.08.023 10.3109/10408363.2015.1023429 10.2174/13816128113196660678 10.1016/j.jacc.2009.10.053 10.1016/j.ijcard.2011.11.028 10.1016/j.jaci.2007.10.018 10.1038/35055575 10.1111/1755-5922.12057 10.1172/JCI29126 10.1016/j.atherosclerosis.2015.05.022 10.1016/j.mce.2014.09.014 10.1073/pnas.0305683101 10.1016/j.atherosclerosis.2013.06.026 10.5551/jat.12.111 10.1016/j.metabol.2006.11.007 10.1016/j.atherosclerosis.2006.08.028 10.1016/S1567-5688(03)00004-7 10.1016/j.atherosclerosis.2009.11.035 10.2174/1381612811319270014 10.2337/diacare.26.10.2713 10.3899/jrheum.100582 10.1161/01.HYP.0000166722.91714.ba 10.5414/CP201735 10.1160/TH14-11-0937 10.1016/S1567-5688(14)70002-9 10.1124/jpet.102.036160 10.1186/s12916-015-0459-4 10.1038/nri1937 10.1016/j.ijcard.2009.07.002 10.1136/bmj.b2535 10.1016/j.jacc.2005.02.052 10.1007/s10557-012-6412-2 10.1016/j.jacl.2010.04.003 10.1007/s12020-009-9278-8 10.1111/j.1365-2265.2007.03080.x 10.2337/db13-0566 10.1016/j.atherosclerosis.2013.01.045 10.5604/20831862.1150298 10.2337/dc09-0738 10.1177/1074248408318628 |
| ContentType | Journal Article |
| Copyright | 2016 Elsevier Ireland Ltd Elsevier Ireland Ltd Copyright © 2016 Elsevier Ireland Ltd. All rights reserved. |
| Copyright_xml | – notice: 2016 Elsevier Ireland Ltd – notice: Elsevier Ireland Ltd – notice: Copyright © 2016 Elsevier Ireland Ltd. All rights reserved. |
| CorporateAuthor | Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group |
| CorporateAuthor_xml | – name: Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.atherosclerosis.2016.07.897 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-1484 |
| EndPage | 208 |
| ExternalDocumentID | 27498397 10_1016_j_atherosclerosis_2016_07_897 S0021915016311984 1_s2_0_S0021915016311984 |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 23N 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABXDB ACDAQ ACGFS ACIEU ACIUM ACLOT ACRLP ACVFH ADBBV ADCNI ADEZE AEBSH AEIPS AEKER AENEX AEUPX AEVXI AEXQZ AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEB HMK HMO HVGLF HZ~ IHE J1W J5H K-O KOM L7B M27 M41 MO0 N9A O-L O9- OAUVE OA~ OK1 OL0 OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K WUQ X7M Z5R ZGI ZXP ~G- ~HD ~KM AACTN AFCTW AFKWA AJOXV AMFUW NCXOZ RIG 0SF AAIAV ABLVK ABYKQ AHPSJ AJBFU LCYCR ZA5 9DU AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c627t-36e5e876bca30c3e21c562621a018147b093d69e7b52abec0785f0d9f13b8c983 |
| ISICitedReferencesCount | 168 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000389401200029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0021-9150 1879-1484 |
| IngestDate | Sat Sep 27 22:47:51 EDT 2025 Mon Jul 21 06:07:45 EDT 2025 Tue Nov 18 21:45:30 EST 2025 Sat Nov 29 06:16:13 EST 2025 Fri Feb 23 02:24:02 EST 2024 Tue Feb 25 19:57:36 EST 2025 Tue Oct 14 19:39:09 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Hydroxymethylglutaryl-CoA reductase inhibitors Statins Adiponectin Meta-analysis |
| Language | English |
| License | Copyright © 2016 Elsevier Ireland Ltd. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c627t-36e5e876bca30c3e21c562621a018147b093d69e7b52abec0785f0d9f13b8c983 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| ORCID | 0000-0001-6690-6874 |
| OpenAccessLink | https://research.birmingham.ac.uk/portal/en/publications/impact-of-statin-therapy-on-plasma-adiponectin-concentrations(0a14fc48-14a6-41d3-b6e7-5f5b5b1cd562).html |
| PMID | 27498397 |
| PQID | 1835359626 |
| PQPubID | 23479 |
| PageCount | 15 |
| ParticipantIDs | proquest_miscellaneous_1835359626 pubmed_primary_27498397 crossref_primary_10_1016_j_atherosclerosis_2016_07_897 crossref_citationtrail_10_1016_j_atherosclerosis_2016_07_897 elsevier_sciencedirect_doi_10_1016_j_atherosclerosis_2016_07_897 elsevier_clinicalkeyesjournals_1_s2_0_S0021915016311984 elsevier_clinicalkey_doi_10_1016_j_atherosclerosis_2016_07_897 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-10-01 |
| PublicationDateYYYYMMDD | 2016-10-01 |
| PublicationDate_xml | – month: 10 year: 2016 text: 2016-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Ireland |
| PublicationPlace_xml | – name: Ireland |
| PublicationTitle | Atherosclerosis |
| PublicationTitleAlternate | Atherosclerosis |
| PublicationYear | 2016 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Chamberlain (bib42) 2001; 507 Amin, Chen, Tannous (bib39) 2002; 303 Fantuzzi (bib33) 2008; 121 El-Barbary, Hussein, Rageh (bib55) 2011; 38 Kostapanos, Milionis, Elisaf (bib45) 2008; 13 Koh, Quon, Han (bib64) 2010; 55 Koh, Quon, Han (bib63) 2009; 204 Keech, Colquhoun, Best (bib34) 2003; 26 Stumvoll, Tschritter, Fritsche (bib8) 2002; 51 Gannagé-Yared, Azar, Amm-Azar (bib58) 2005; 54 Koh, Quon, Han (bib71) 2004; 110 Rajpathak, Kumbhani, Crandall (bib35) 2009; 32 Chapman, Orsoni, Robillard (bib48) 2014; 30 Chan, Chou, Huang (bib52) 2008; 31 Park, Park, Sweeney (bib4) 2015; 52 Roberto, Pasquale, Simona (bib74) 2010; 213 Sawara, Takei, Uchida (bib75) 2008; 47 Jin, Sun, Huang (bib30) 2015; 411 Koh, Quon, Han (bib62) 2005; 45 Lee, Hong, Han (bib19) 2015; 32 Koh, Quon, Sakuma (bib67) 2013; 166 Stępień, Stępień, Banach (bib12) 2014; 65 Abel, Peroni, Kim (bib43) 2001; 409 Koh, Quon, Han (bib61) 2005; 45 Koh, Quon, Han (bib65) 2011; 146 Khan, Wang, Sowers (bib6) 2012; 61 Hozo, Djulbegovic, Hozo (bib26) 2005; 5 Stepien, Rosniak-Bak, Paradowski (bib14) 2011; 17 Yokoyama, Saito, Daitoku (bib79) 2011; 25 Forst, Pfützner, Lübben (bib57) 2007; 56 Banach, Malodobra-Mazur, Gluba (bib22) 2013; 19 Banach, Serban, Ursoniu (bib40) 2015; 99 McTaggart (bib47) 2003; 4 Krysiak, Zmuda, Okopien (bib70) 2014; 32 Moher, Liberati, Tetzlaff (bib23) 2009; 339 Stępień, Wlazeł, Paradowski (bib13) 2012; 8 Higgins, Green (bib24) 2011; 5 Serban, Sahebkar, Ursoniu (bib31) 2015; 5 Zhang, Li, Corcoran (bib3) 2015; 399 Nigro, Scudiero, Monaco (bib15) 2014; 2014 Kei, Rizos, Elisaf (bib36) 2015; 6 Hui, Lam, Vanhoutte (bib16) 2012; 165 Duval, Tweedie (bib28) 2000; 56 Greenhill (bib10) 2015; 11 Barylski, Nikolic, Banach (bib38) 2014; 20 Sahebkar, Kotani, Serban (bib21) 2015; 241 Kim, Lee, Shin (bib60) 2013; 227 Koh, Quon, Han (bib69) 2008; 31 Koh, Lim, Choi (bib68) 2013; 62 Banach, Serban, Sahebkar (bib20) 2015; 13 Sutton, Abrams, Jones (bib27) 2000 Fichtenbaum, Yeh, Evans (bib56) 2010; 4 Nomura, Inami, Shouzu (bib73) 2009; 20 Nakamura, Kodama, Takano (bib72) 2007; 193 Doh, Chang, Koo (bib54) 2012; 26 Hossain, Mukheem, Kamarul (bib18) 2015; 135 Buldak, Dulawa-Buldak, Labuzek (bib51) 2012; 50 Brochu-Gaudreau, Rehfeldt, Blouin (bib17) 2010; 37 Kadowaki, Yamauchi, Kubota (bib9) 2006; 116 van Hoek, van Tol, van Vark-Van der Zee (bib78) 2008; 25 Koh, Quon, Sakuma (bib66) 2011; 146 Arnaboldi, Corsini (bib46) 2015; 16 Fan, He, Xu (bib49) 2015; 31 Shetty, Economides, Horton (bib76) 2004; 27 Gazzerro, Proto, Gangemi (bib50) 2012; 64 Maedler, Sergeev, Ehses (bib44) 2004; 101 Karastergiou (bib7) 2015 Mabuchi, Higashikata, Kawashiri (bib41) 2005; 12 Elfakhani, Torabi, Hussein (bib37) 2014; 239 Tilg, Moschen (bib1) 2006; 6 Sahebkar, Watts (bib29) 2013; 230 Ohashi, Yuasa, Shibata (bib11) 2015; 15 Borenstein, Hedges, Higgins (bib25) 2005 Sahebkar, Serban, Mikhailidis (bib32) 2015; 114 Jung, Choi (bib2) 2014; 15 Gouni-Berthold, Berthold, Chamberland (bib59) 2008; 68 Devaraj, Siegel, Jialal (bib53) 2007; 100 Hu, Tong, Xu (bib80) 2009; 6 Heid, Henneman, Hicks (bib5) 2010; 208 Sugiyama, Fukushima, Kugiyama (bib77) 2007; 194 Khan (10.1016/j.atherosclerosis.2016.07.897_bib6) 2012; 61 Brochu-Gaudreau (10.1016/j.atherosclerosis.2016.07.897_bib17) 2010; 37 Duval (10.1016/j.atherosclerosis.2016.07.897_bib28) 2000; 56 Hui (10.1016/j.atherosclerosis.2016.07.897_bib16) 2012; 165 Amin (10.1016/j.atherosclerosis.2016.07.897_bib39) 2002; 303 Tilg (10.1016/j.atherosclerosis.2016.07.897_bib1) 2006; 6 Koh (10.1016/j.atherosclerosis.2016.07.897_bib69) 2008; 31 Stępień (10.1016/j.atherosclerosis.2016.07.897_bib13) 2012; 8 Hossain (10.1016/j.atherosclerosis.2016.07.897_bib18) 2015; 135 Sahebkar (10.1016/j.atherosclerosis.2016.07.897_bib21) 2015; 241 Sahebkar (10.1016/j.atherosclerosis.2016.07.897_bib29) 2013; 230 Nakamura (10.1016/j.atherosclerosis.2016.07.897_bib72) 2007; 193 Higgins (10.1016/j.atherosclerosis.2016.07.897_bib24) 2011; 5 Nomura (10.1016/j.atherosclerosis.2016.07.897_bib73) 2009; 20 Barylski (10.1016/j.atherosclerosis.2016.07.897_bib38) 2014; 20 Stępień (10.1016/j.atherosclerosis.2016.07.897_bib12) 2014; 65 Sugiyama (10.1016/j.atherosclerosis.2016.07.897_bib77) 2007; 194 Karastergiou (10.1016/j.atherosclerosis.2016.07.897_bib7) 2015 Forst (10.1016/j.atherosclerosis.2016.07.897_bib57) 2007; 56 Koh (10.1016/j.atherosclerosis.2016.07.897_bib63) 2009; 204 El-Barbary (10.1016/j.atherosclerosis.2016.07.897_bib55) 2011; 38 Gouni-Berthold (10.1016/j.atherosclerosis.2016.07.897_bib59) 2008; 68 Koh (10.1016/j.atherosclerosis.2016.07.897_bib61) 2005; 45 McTaggart (10.1016/j.atherosclerosis.2016.07.897_bib47) 2003; 4 Lee (10.1016/j.atherosclerosis.2016.07.897_bib19) 2015; 32 Chapman (10.1016/j.atherosclerosis.2016.07.897_bib48) 2014; 30 Banach (10.1016/j.atherosclerosis.2016.07.897_bib20) 2015; 13 Sahebkar (10.1016/j.atherosclerosis.2016.07.897_bib32) 2015; 114 Park (10.1016/j.atherosclerosis.2016.07.897_bib4) 2015; 52 Hozo (10.1016/j.atherosclerosis.2016.07.897_bib26) 2005; 5 Koh (10.1016/j.atherosclerosis.2016.07.897_bib66) 2011; 146 Jin (10.1016/j.atherosclerosis.2016.07.897_bib30) 2015; 411 Kei (10.1016/j.atherosclerosis.2016.07.897_bib36) 2015; 6 Kim (10.1016/j.atherosclerosis.2016.07.897_bib60) 2013; 227 Elfakhani (10.1016/j.atherosclerosis.2016.07.897_bib37) 2014; 239 Koh (10.1016/j.atherosclerosis.2016.07.897_bib67) 2013; 166 Kadowaki (10.1016/j.atherosclerosis.2016.07.897_bib9) 2006; 116 Chamberlain (10.1016/j.atherosclerosis.2016.07.897_bib42) 2001; 507 Moher (10.1016/j.atherosclerosis.2016.07.897_bib23) 2009; 339 Koh (10.1016/j.atherosclerosis.2016.07.897_bib65) 2011; 146 Koh (10.1016/j.atherosclerosis.2016.07.897_bib62) 2005; 45 Doh (10.1016/j.atherosclerosis.2016.07.897_bib54) 2012; 26 Sawara (10.1016/j.atherosclerosis.2016.07.897_bib75) 2008; 47 van Hoek (10.1016/j.atherosclerosis.2016.07.897_bib78) 2008; 25 Gannagé-Yared (10.1016/j.atherosclerosis.2016.07.897_bib58) 2005; 54 Koh (10.1016/j.atherosclerosis.2016.07.897_bib64) 2010; 55 Maedler (10.1016/j.atherosclerosis.2016.07.897_bib44) 2004; 101 Kostapanos (10.1016/j.atherosclerosis.2016.07.897_bib45) 2008; 13 Heid (10.1016/j.atherosclerosis.2016.07.897_bib5) 2010; 208 Gazzerro (10.1016/j.atherosclerosis.2016.07.897_bib50) 2012; 64 Stepien (10.1016/j.atherosclerosis.2016.07.897_bib14) 2011; 17 Fantuzzi (10.1016/j.atherosclerosis.2016.07.897_bib33) 2008; 121 Jung (10.1016/j.atherosclerosis.2016.07.897_bib2) 2014; 15 Banach (10.1016/j.atherosclerosis.2016.07.897_bib40) 2015; 99 Yokoyama (10.1016/j.atherosclerosis.2016.07.897_bib79) 2011; 25 Hu (10.1016/j.atherosclerosis.2016.07.897_bib80) 2009; 6 Abel (10.1016/j.atherosclerosis.2016.07.897_bib43) 2001; 409 Greenhill (10.1016/j.atherosclerosis.2016.07.897_bib10) 2015; 11 Koh (10.1016/j.atherosclerosis.2016.07.897_bib68) 2013; 62 Roberto (10.1016/j.atherosclerosis.2016.07.897_bib74) 2010; 213 Zhang (10.1016/j.atherosclerosis.2016.07.897_bib3) 2015; 399 Nigro (10.1016/j.atherosclerosis.2016.07.897_bib15) 2014; 2014 Shetty (10.1016/j.atherosclerosis.2016.07.897_bib76) 2004; 27 Devaraj (10.1016/j.atherosclerosis.2016.07.897_bib53) 2007; 100 Stumvoll (10.1016/j.atherosclerosis.2016.07.897_bib8) 2002; 51 Arnaboldi (10.1016/j.atherosclerosis.2016.07.897_bib46) 2015; 16 Fichtenbaum (10.1016/j.atherosclerosis.2016.07.897_bib56) 2010; 4 Keech (10.1016/j.atherosclerosis.2016.07.897_bib34) 2003; 26 Mabuchi (10.1016/j.atherosclerosis.2016.07.897_bib41) 2005; 12 Ohashi (10.1016/j.atherosclerosis.2016.07.897_bib11) 2015; 15 Krysiak (10.1016/j.atherosclerosis.2016.07.897_bib70) 2014; 32 Chan (10.1016/j.atherosclerosis.2016.07.897_bib52) 2008; 31 Buldak (10.1016/j.atherosclerosis.2016.07.897_bib51) 2012; 50 Banach (10.1016/j.atherosclerosis.2016.07.897_bib22) 2013; 19 Koh (10.1016/j.atherosclerosis.2016.07.897_bib71) 2004; 110 Sutton (10.1016/j.atherosclerosis.2016.07.897_bib27) 2000 Rajpathak (10.1016/j.atherosclerosis.2016.07.897_bib35) 2009; 32 Fan (10.1016/j.atherosclerosis.2016.07.897_bib49) 2015; 31 Borenstein (10.1016/j.atherosclerosis.2016.07.897_bib25) 2005 Serban (10.1016/j.atherosclerosis.2016.07.897_bib31) 2015; 5 27567030 - Atherosclerosis. 2016 Oct;253:270-272. doi: 10.1016/j.atherosclerosis.2016.08.009. |
| References_xml | – volume: 15 start-page: 145 year: 2015 end-page: 150 ident: bib11 article-title: Adiponectin as a target in obesity-related inflammatory state, endocrine publication-title: Metabol. Immune Disorders Drug Targets Formerly Curr. Drug Targets ImmuneEndocr. Metabol. Disord. – volume: 101 start-page: 8138 year: 2004 end-page: 8143 ident: bib44 article-title: Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 54 start-page: 947 year: 2005 end-page: 951 ident: bib58 article-title: Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients publication-title: Metabolism – volume: 31 start-page: 955 year: 2015 end-page: 958 ident: bib49 article-title: Adiponectin may be a biomarker of early atherosclerosis of smokers and decreased by nicotine through KATP channel in adipocytes publication-title: Nutr. (Burbank, Los Angel. Cty. Calif.) – volume: 61 start-page: 1261 year: 2012 end-page: 1269 ident: bib6 article-title: Race–ethnic differences in adipokine levels: the Study of Women's Health across the Nation (SWAN) publication-title: Metabol. Clin. Exp. – volume: 100 start-page: 1397 year: 2007 end-page: 1399 ident: bib53 article-title: Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome publication-title: Am. J. Cardiol. – volume: 37 start-page: 11 year: 2010 end-page: 32 ident: bib17 article-title: Adiponectin action from head to toe publication-title: Endocrine – volume: 6 start-page: 246 year: 2015 end-page: 251 ident: bib36 article-title: Statin use in prediabetic patients: rationale and results to date publication-title: Ther. Adv. Chronic Dis. – volume: 146 start-page: 434 year: 2011 end-page: 437 ident: bib66 article-title: Effects of simvastatin therapy on circulating adipocytokines in patients with hypercholesterolemia publication-title: Int. J. Cardiol. – volume: 227 start-page: 355 year: 2013 end-page: 359 ident: bib60 article-title: Effects of pravastatin on serum adiponectin levels in female patients with type 2 diabetes mellitus publication-title: Atherosclerosis – volume: 146 start-page: 319 year: 2011 end-page: 325 ident: bib65 article-title: Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension publication-title: Int. J. Cardiol. – volume: 32 start-page: 1924 year: 2009 end-page: 1929 ident: bib35 article-title: Statin therapy and risk of developing type 2 diabetes: a meta-analysis publication-title: Diabetes care – volume: 20 start-page: 16 year: 2009 end-page: 22 ident: bib73 article-title: The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients publication-title: Platelets – volume: 8 start-page: 431 year: 2012 end-page: 436 ident: bib13 article-title: Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo-and hypertensive patients–pilot study publication-title: Arch. Med. Sci. – volume: 65 start-page: 333 year: 2014 end-page: 342 ident: bib12 article-title: New obesity indices and adipokines in normotensive patients and patients with hypertension comparative pilot analysis publication-title: Angiology – volume: 26 start-page: 501 year: 2012 end-page: 509 ident: bib54 article-title: The effect of HMG-CoA reductase inhibitor on insulin resistance in patients undergoing peritoneal dialysis publication-title: Cardiovasc. drugs Ther. – volume: 6 start-page: 262 year: 2009 end-page: 268 ident: bib80 article-title: Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis publication-title: Diabetes Vasc. Dis. Res. – volume: 45 start-page: 1088 year: 2005 end-page: 1093 ident: bib62 article-title: Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes publication-title: Hypertension – volume: 208 start-page: 412 year: 2010 end-page: 420 ident: bib5 article-title: Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals publication-title: Atherosclerosis – volume: 11 year: 2015 ident: bib10 article-title: Epigenetics: obesity-induced hypermethylation of adiponectin gene, nature reviews publication-title: Endocrinology – volume: 30 start-page: 775 year: 2014 end-page: 784 ident: bib48 article-title: Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies publication-title: Curr. Med. Res. Opin. – volume: 62 start-page: 3547 year: 2013 end-page: 3552 ident: bib68 article-title: Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia publication-title: Diabetes – volume: 135 start-page: 55 year: 2015 end-page: 67 ident: bib18 article-title: The prevention and treatment of hypoadiponectinemia-associated human diseases by up-regulation of plasma adiponectin publication-title: Life Sci. – volume: 51 start-page: 37 year: 2002 end-page: 41 ident: bib8 article-title: Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes publication-title: Diabetes – volume: 17 start-page: PR13 year: 2011 end-page: PR18 ident: bib14 article-title: Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: preliminary results publication-title: Med. Sci. Monit. Basic Res. – volume: 204 start-page: 483 year: 2009 end-page: 490 ident: bib63 article-title: Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients publication-title: Atherosclerosis – volume: 507 start-page: 357 year: 2001 end-page: 361 ident: bib42 article-title: Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes publication-title: FEBS Lett. – volume: 121 start-page: 326 year: 2008 end-page: 330 ident: bib33 article-title: Adiponectin and inflammation: consensus and controversy publication-title: J. Allergy Clin. Immunol. – volume: 26 start-page: 2713 year: 2003 end-page: 2721 ident: bib34 article-title: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial publication-title: Diabetes Care – volume: 194 start-page: e43 year: 2007 end-page: e51 ident: bib77 article-title: Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease publication-title: Atherosclerosis – volume: 56 start-page: 491 year: 2007 end-page: 496 ident: bib57 article-title: Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk—the PIOSTAT Study publication-title: Metabolism – volume: 15 start-page: 6184 year: 2014 end-page: 6223 ident: bib2 article-title: Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease publication-title: Int. J. Mol. Sci. – volume: 5 year: 2011 ident: bib24 article-title: Cochrane handbook for systematic reviews of interventions version 5.1. 0 publication-title: Cochrane Collab. – volume: 25 start-page: 378 year: 2011 end-page: 387 ident: bib79 article-title: Effects of pravastatin and rosuvastatin on the generation of adiponectin in the visceral adipose tissue in patients with coronary artery disease publication-title: Fundam. Clin. Pharmacol. – volume: 16 start-page: 1 year: 2015 end-page: 27 ident: bib46 article-title: Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin publication-title: Atherosclerosis – volume: 64 start-page: 102 year: 2012 end-page: 146 ident: bib50 article-title: Pharmacological actions of statins: a critical appraisal in the management of cancer publication-title: Pharmacol. Rev. – volume: 303 start-page: 82 year: 2002 end-page: 88 ident: bib39 article-title: Inhibition of glucose-and calcium-induced insulin secretion from βTC3 cells by novel inhibitors of protein isoprenylation publication-title: J. Pharmacol. Exp. Ther. – volume: 4 start-page: 9 year: 2003 end-page: 14 ident: bib47 article-title: Comparative pharmacology of rosuvastatin publication-title: Atherosclerosis – volume: 19 start-page: 4904 year: 2013 end-page: 4912 ident: bib22 article-title: Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance publication-title: Curr. Pharm. Des. – volume: 68 start-page: 536 year: 2008 end-page: 541 ident: bib59 article-title: Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men publication-title: Clin. Endocrinol. – volume: 45 start-page: 1649 year: 2005 end-page: 1653 ident: bib61 article-title: Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia publication-title: J. Am. Coll. Cardiol. – volume: 2014 start-page: 658913 year: 2014 ident: bib15 article-title: New insight into adiponectin role in obesity and obesity-related diseases publication-title: BioMed Res. Int. – volume: 55 start-page: 1209 year: 2010 end-page: 1216 ident: bib64 article-title: Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients publication-title: J. Am. Coll. Cardiol. – volume: 411 start-page: 97 year: 2015 end-page: 104 ident: bib30 article-title: Peroxisome proliferator-activated receptor gamma enhances adiponectin secretion via up-regulating DsbA-L expression publication-title: Mol. Cell Endocrinol. – volume: 193 start-page: 449 year: 2007 end-page: 451 ident: bib72 article-title: Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia publication-title: Atherosclerosis – volume: 339 start-page: b2535 year: 2009 ident: bib23 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: BMJ – volume: 31 start-page: 776 year: 2008 end-page: 782 ident: bib69 article-title: Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients publication-title: Diabetes Care – volume: 116 start-page: 1784 year: 2006 end-page: 1792 ident: bib9 article-title: Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome publication-title: J. Clin. Invest. – volume: 47 start-page: 1505 year: 2008 end-page: 1510 ident: bib75 article-title: Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease publication-title: Intern. Med. – volume: 27 start-page: 2450 year: 2004 end-page: 2457 ident: bib76 article-title: Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes publication-title: Diabetes Care – volume: 5 start-page: 9902 year: 2015 ident: bib31 article-title: A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations publication-title: Sci. Rep. – volume: 52 start-page: 180 year: 2015 end-page: 190 ident: bib4 article-title: Biomarkers of insulin sensitivity and insulin resistance: past, present and future publication-title: Crit. Rev. Clin. Lab. Sci. – volume: 50 start-page: 805 year: 2012 end-page: 813 ident: bib51 article-title: Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose publication-title: Int. J. Clin. Pharmacol. Ther. – volume: 13 start-page: 157 year: 2008 end-page: 174 ident: bib45 article-title: An overview of the extra-lipid effects of rosuvastatin publication-title: J. Cardiovasc Pharmacol. Ther. – volume: 230 start-page: 110 year: 2013 end-page: 120 ident: bib29 article-title: Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials publication-title: Atherosclerosis – volume: 239 start-page: 293 year: 2014 end-page: 301 ident: bib37 article-title: Mevalonate deprivation mediates the impact of lovastatin on the differentiation of murine 3T3-F442A preadipocytes publication-title: Exp. Biol. Med. – volume: 32 start-page: 40 year: 2014 end-page: 46 ident: bib70 article-title: The effect of simvastatin–ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia publication-title: Cardiovasc. Ther. – volume: 166 start-page: 509 year: 2013 end-page: 515 ident: bib67 article-title: Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients publication-title: Int. J. Cardiol. – volume: 110 start-page: 3687 year: 2004 end-page: 3692 ident: bib71 article-title: Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients publication-title: Circulation – volume: 56 start-page: 455 year: 2000 end-page: 463 ident: bib28 article-title: Trim and fill: a simple funnel-plot–based method of testing and adjusting for publication bias in meta-analysis publication-title: Biometrics – start-page: 104 year: 2005 ident: bib25 article-title: Comprehensive Meta-analysis Version 2 – volume: 99 start-page: 329 year: 2015 end-page: 336 ident: bib40 article-title: Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials publication-title: Pharmacol. Res. – volume: 241 start-page: 433 year: 2015 end-page: 442 ident: bib21 article-title: Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials publication-title: Atherosclerosis – volume: 114 start-page: 546 year: 2015 end-page: 557 ident: bib32 article-title: Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials publication-title: Thromb. Haemost. – volume: 399 start-page: 164 year: 2015 end-page: 177 ident: bib3 article-title: Essential roles of insulin, AMPK signaling and lysyl and prolyl hydroxylases in the biosynthesis and multimerization of adiponectin publication-title: Mol. Cell. Endocrinol. – volume: 31 start-page: 253 year: 2008 end-page: 258 ident: bib52 article-title: Atorvastatin administration after percutaneous coronary intervention in patients with coronary artery disease and normal lipid profiles: impact on plasma adiponectin level publication-title: Clin. Cardiol. – volume: 5 start-page: 13 year: 2005 ident: bib26 article-title: Estimating the mean and variance from the median, range, and the size of a sample publication-title: BMC Med. Res. Methodol. – volume: 38 start-page: 229 year: 2011 end-page: 235 ident: bib55 article-title: Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis publication-title: J. Rheumatol. – volume: 6 start-page: 772 year: 2006 end-page: 783 ident: bib1 article-title: Adipocytokines: mediators linking adipose tissue, inflammation and immunity publication-title: Nat. Rev. Immunol. – year: 2000 ident: bib27 article-title: Methods for Meta-analysis in Medical Research – volume: 165 start-page: 574 year: 2012 end-page: 590 ident: bib16 article-title: Adiponectin and cardiovascular health: an update publication-title: Br. J. Pharmacol. – volume: 213 start-page: 225 year: 2010 end-page: 234 ident: bib74 article-title: Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients publication-title: Atherosclerosis – volume: 12 start-page: 111 year: 2005 end-page: 119 ident: bib41 article-title: Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients publication-title: J. Atheroscler. Thromb. – volume: 32 start-page: 181 year: 2015 ident: bib19 article-title: Aerobic training increases the expression of adiponectin receptor genes in the peripheral blood mononuclear cells of young men publication-title: Biol. sport – volume: 409 start-page: 729 year: 2001 end-page: 733 ident: bib43 article-title: Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver publication-title: Nature – start-page: 1 year: 2015 end-page: 10 ident: bib7 article-title: The interplay between sex, ethnicity, and adipose tissue characteristics publication-title: Curr. Obes. Rep. – volume: 13 start-page: 229 year: 2015 ident: bib20 article-title: Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies publication-title: BMC Med. – volume: 4 start-page: 279 year: 2010 end-page: 287 ident: bib56 article-title: Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087 publication-title: J. Clin. Lipidol. – volume: 25 start-page: 93 year: 2008 end-page: 101 ident: bib78 article-title: Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes* publication-title: Curr. Med. Res. Opinion – volume: 20 start-page: 3657 year: 2014 end-page: 3664 ident: bib38 article-title: Statins and new-onset diabetes publication-title: Curr. Pharm. Des. – volume: 213 start-page: 225 year: 2010 ident: 10.1016/j.atherosclerosis.2016.07.897_bib74 article-title: Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2010.08.056 – volume: 5 start-page: 13 year: 2005 ident: 10.1016/j.atherosclerosis.2016.07.897_bib26 article-title: Estimating the mean and variance from the median, range, and the size of a sample publication-title: BMC Med. Res. Methodol. doi: 10.1186/1471-2288-5-13 – volume: 47 start-page: 1505 year: 2008 ident: 10.1016/j.atherosclerosis.2016.07.897_bib75 article-title: Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease publication-title: Intern. Med. doi: 10.2169/internalmedicine.47.1159 – volume: 204 start-page: 483 year: 2009 ident: 10.1016/j.atherosclerosis.2016.07.897_bib63 article-title: Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2008.09.021 – volume: 5 year: 2011 ident: 10.1016/j.atherosclerosis.2016.07.897_bib24 article-title: Cochrane handbook for systematic reviews of interventions version 5.1. 0 publication-title: Cochrane Collab. – volume: 27 start-page: 2450 year: 2004 ident: 10.1016/j.atherosclerosis.2016.07.897_bib76 article-title: Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes publication-title: Diabetes Care doi: 10.2337/diacare.27.10.2450 – volume: 99 start-page: 329 year: 2015 ident: 10.1016/j.atherosclerosis.2016.07.897_bib40 article-title: Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2015.07.008 – volume: 6 start-page: 262 year: 2009 ident: 10.1016/j.atherosclerosis.2016.07.897_bib80 article-title: Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis publication-title: Diabetes Vasc. Dis. Res. doi: 10.1177/1479164109339966 – start-page: 104 year: 2005 ident: 10.1016/j.atherosclerosis.2016.07.897_bib25 – start-page: 1 year: 2015 ident: 10.1016/j.atherosclerosis.2016.07.897_bib7 article-title: The interplay between sex, ethnicity, and adipose tissue characteristics publication-title: Curr. Obes. Rep. – volume: 6 start-page: 246 year: 2015 ident: 10.1016/j.atherosclerosis.2016.07.897_bib36 article-title: Statin use in prediabetic patients: rationale and results to date publication-title: Ther. Adv. Chronic Dis. doi: 10.1177/2040622315596118 – volume: 64 start-page: 102 year: 2012 ident: 10.1016/j.atherosclerosis.2016.07.897_bib50 article-title: Pharmacological actions of statins: a critical appraisal in the management of cancer publication-title: Pharmacol. Rev. doi: 10.1124/pr.111.004994 – volume: 25 start-page: 378 year: 2011 ident: 10.1016/j.atherosclerosis.2016.07.897_bib79 article-title: Effects of pravastatin and rosuvastatin on the generation of adiponectin in the visceral adipose tissue in patients with coronary artery disease publication-title: Fundam. Clin. Pharmacol. doi: 10.1111/j.1472-8206.2010.00847.x – volume: 30 start-page: 775 year: 2014 ident: 10.1016/j.atherosclerosis.2016.07.897_bib48 article-title: Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies publication-title: Curr. Med. Res. Opin. doi: 10.1185/03007995.2013.874989 – volume: 239 start-page: 293 year: 2014 ident: 10.1016/j.atherosclerosis.2016.07.897_bib37 article-title: Mevalonate deprivation mediates the impact of lovastatin on the differentiation of murine 3T3-F442A preadipocytes publication-title: Exp. Biol. Med. doi: 10.1177/1535370213517614 – volume: 31 start-page: 776 year: 2008 ident: 10.1016/j.atherosclerosis.2016.07.897_bib69 article-title: Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients publication-title: Diabetes Care doi: 10.2337/dc07-2199 – volume: 165 start-page: 574 year: 2012 ident: 10.1016/j.atherosclerosis.2016.07.897_bib16 article-title: Adiponectin and cardiovascular health: an update publication-title: Br. J. Pharmacol. doi: 10.1111/j.1476-5381.2011.01395.x – volume: 54 start-page: 947 year: 2005 ident: 10.1016/j.atherosclerosis.2016.07.897_bib58 article-title: Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients publication-title: Metabolism doi: 10.1016/j.metabol.2005.02.011 – volume: 146 start-page: 434 year: 2011 ident: 10.1016/j.atherosclerosis.2016.07.897_bib66 article-title: Effects of simvastatin therapy on circulating adipocytokines in patients with hypercholesterolemia publication-title: Int. J. Cardiol. doi: 10.1016/j.ijcard.2010.10.103 – volume: 25 start-page: 93 year: 2008 ident: 10.1016/j.atherosclerosis.2016.07.897_bib78 article-title: Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes* publication-title: Curr. Med. Res. Opinion doi: 10.1185/03007990802596813 – volume: 15 start-page: 6184 year: 2014 ident: 10.1016/j.atherosclerosis.2016.07.897_bib2 article-title: Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms15046184 – volume: 31 start-page: 955 year: 2015 ident: 10.1016/j.atherosclerosis.2016.07.897_bib49 article-title: Adiponectin may be a biomarker of early atherosclerosis of smokers and decreased by nicotine through KATP channel in adipocytes publication-title: Nutr. (Burbank, Los Angel. Cty. Calif.) doi: 10.1016/j.nut.2015.01.010 – volume: 15 start-page: 145 year: 2015 ident: 10.1016/j.atherosclerosis.2016.07.897_bib11 article-title: Adiponectin as a target in obesity-related inflammatory state, endocrine publication-title: Metabol. Immune Disorders Drug Targets Formerly Curr. Drug Targets ImmuneEndocr. Metabol. Disord. – volume: 411 start-page: 97 year: 2015 ident: 10.1016/j.atherosclerosis.2016.07.897_bib30 article-title: Peroxisome proliferator-activated receptor gamma enhances adiponectin secretion via up-regulating DsbA-L expression publication-title: Mol. Cell Endocrinol. doi: 10.1016/j.mce.2015.04.015 – volume: 2014 start-page: 658913 year: 2014 ident: 10.1016/j.atherosclerosis.2016.07.897_bib15 article-title: New insight into adiponectin role in obesity and obesity-related diseases publication-title: BioMed Res. Int. doi: 10.1155/2014/658913 – volume: 56 start-page: 455 year: 2000 ident: 10.1016/j.atherosclerosis.2016.07.897_bib28 article-title: Trim and fill: a simple funnel-plot–based method of testing and adjusting for publication bias in meta-analysis publication-title: Biometrics doi: 10.1111/j.0006-341X.2000.00455.x – volume: 65 start-page: 333 year: 2014 ident: 10.1016/j.atherosclerosis.2016.07.897_bib12 article-title: New obesity indices and adipokines in normotensive patients and patients with hypertension comparative pilot analysis publication-title: Angiology doi: 10.1177/0003319713485807 – volume: 8 start-page: 431 year: 2012 ident: 10.1016/j.atherosclerosis.2016.07.897_bib13 article-title: Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo-and hypertensive patients–pilot study publication-title: Arch. Med. Sci. doi: 10.5114/aoms.2012.29518 – volume: 100 start-page: 1397 year: 2007 ident: 10.1016/j.atherosclerosis.2016.07.897_bib53 article-title: Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome publication-title: Am. J. Cardiol. doi: 10.1016/j.amjcard.2007.06.028 – volume: 17 start-page: PR13 year: 2011 ident: 10.1016/j.atherosclerosis.2016.07.897_bib14 article-title: Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: preliminary results publication-title: Med. Sci. Monit. Basic Res. – volume: 110 start-page: 3687 year: 2004 ident: 10.1016/j.atherosclerosis.2016.07.897_bib71 article-title: Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients publication-title: Circulation doi: 10.1161/01.CIR.0000143085.86697.13 – volume: 135 start-page: 55 year: 2015 ident: 10.1016/j.atherosclerosis.2016.07.897_bib18 article-title: The prevention and treatment of hypoadiponectinemia-associated human diseases by up-regulation of plasma adiponectin publication-title: Life Sci. doi: 10.1016/j.lfs.2015.03.010 – volume: 20 start-page: 16 year: 2009 ident: 10.1016/j.atherosclerosis.2016.07.897_bib73 article-title: The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients publication-title: Platelets doi: 10.1080/09537100802409921 – volume: 51 start-page: 37 year: 2002 ident: 10.1016/j.atherosclerosis.2016.07.897_bib8 article-title: Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes publication-title: Diabetes doi: 10.2337/diabetes.51.1.37 – volume: 31 start-page: 253 year: 2008 ident: 10.1016/j.atherosclerosis.2016.07.897_bib52 article-title: Atorvastatin administration after percutaneous coronary intervention in patients with coronary artery disease and normal lipid profiles: impact on plasma adiponectin level publication-title: Clin. Cardiol. doi: 10.1002/clc.20181 – volume: 507 start-page: 357 year: 2001 ident: 10.1016/j.atherosclerosis.2016.07.897_bib42 article-title: Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes publication-title: FEBS Lett. doi: 10.1016/S0014-5793(01)03007-1 – volume: 61 start-page: 1261 year: 2012 ident: 10.1016/j.atherosclerosis.2016.07.897_bib6 article-title: Race–ethnic differences in adipokine levels: the Study of Women's Health across the Nation (SWAN) publication-title: Metabol. Clin. Exp. doi: 10.1016/j.metabol.2012.02.005 – volume: 5 start-page: 9902 year: 2015 ident: 10.1016/j.atherosclerosis.2016.07.897_bib31 article-title: A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations publication-title: Sci. Rep. doi: 10.1038/srep09902 – volume: 194 start-page: e43 year: 2007 ident: 10.1016/j.atherosclerosis.2016.07.897_bib77 article-title: Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2006.08.023 – volume: 52 start-page: 180 year: 2015 ident: 10.1016/j.atherosclerosis.2016.07.897_bib4 article-title: Biomarkers of insulin sensitivity and insulin resistance: past, present and future publication-title: Crit. Rev. Clin. Lab. Sci. doi: 10.3109/10408363.2015.1023429 – volume: 20 start-page: 3657 year: 2014 ident: 10.1016/j.atherosclerosis.2016.07.897_bib38 article-title: Statins and new-onset diabetes publication-title: Curr. Pharm. Des. doi: 10.2174/13816128113196660678 – volume: 55 start-page: 1209 year: 2010 ident: 10.1016/j.atherosclerosis.2016.07.897_bib64 article-title: Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2009.10.053 – volume: 166 start-page: 509 year: 2013 ident: 10.1016/j.atherosclerosis.2016.07.897_bib67 article-title: Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients publication-title: Int. J. Cardiol. doi: 10.1016/j.ijcard.2011.11.028 – volume: 121 start-page: 326 year: 2008 ident: 10.1016/j.atherosclerosis.2016.07.897_bib33 article-title: Adiponectin and inflammation: consensus and controversy publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2007.10.018 – volume: 409 start-page: 729 year: 2001 ident: 10.1016/j.atherosclerosis.2016.07.897_bib43 article-title: Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver publication-title: Nature doi: 10.1038/35055575 – volume: 32 start-page: 40 year: 2014 ident: 10.1016/j.atherosclerosis.2016.07.897_bib70 article-title: The effect of simvastatin–ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia publication-title: Cardiovasc. Ther. doi: 10.1111/1755-5922.12057 – volume: 116 start-page: 1784 year: 2006 ident: 10.1016/j.atherosclerosis.2016.07.897_bib9 article-title: Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome publication-title: J. Clin. Invest. doi: 10.1172/JCI29126 – volume: 241 start-page: 433 year: 2015 ident: 10.1016/j.atherosclerosis.2016.07.897_bib21 article-title: Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2015.05.022 – volume: 399 start-page: 164 year: 2015 ident: 10.1016/j.atherosclerosis.2016.07.897_bib3 article-title: Essential roles of insulin, AMPK signaling and lysyl and prolyl hydroxylases in the biosynthesis and multimerization of adiponectin publication-title: Mol. Cell. Endocrinol. doi: 10.1016/j.mce.2014.09.014 – volume: 101 start-page: 8138 year: 2004 ident: 10.1016/j.atherosclerosis.2016.07.897_bib44 article-title: Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.0305683101 – year: 2000 ident: 10.1016/j.atherosclerosis.2016.07.897_bib27 – volume: 230 start-page: 110 year: 2013 ident: 10.1016/j.atherosclerosis.2016.07.897_bib29 article-title: Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2013.06.026 – volume: 12 start-page: 111 year: 2005 ident: 10.1016/j.atherosclerosis.2016.07.897_bib41 article-title: Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients publication-title: J. Atheroscler. Thromb. doi: 10.5551/jat.12.111 – volume: 56 start-page: 491 year: 2007 ident: 10.1016/j.atherosclerosis.2016.07.897_bib57 article-title: Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk—the PIOSTAT Study publication-title: Metabolism doi: 10.1016/j.metabol.2006.11.007 – volume: 193 start-page: 449 year: 2007 ident: 10.1016/j.atherosclerosis.2016.07.897_bib72 article-title: Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2006.08.028 – volume: 4 start-page: 9 year: 2003 ident: 10.1016/j.atherosclerosis.2016.07.897_bib47 article-title: Comparative pharmacology of rosuvastatin publication-title: Atherosclerosis doi: 10.1016/S1567-5688(03)00004-7 – volume: 208 start-page: 412 year: 2010 ident: 10.1016/j.atherosclerosis.2016.07.897_bib5 article-title: Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2009.11.035 – volume: 19 start-page: 4904 year: 2013 ident: 10.1016/j.atherosclerosis.2016.07.897_bib22 article-title: Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance publication-title: Curr. Pharm. Des. doi: 10.2174/1381612811319270014 – volume: 26 start-page: 2713 year: 2003 ident: 10.1016/j.atherosclerosis.2016.07.897_bib34 article-title: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial publication-title: Diabetes Care doi: 10.2337/diacare.26.10.2713 – volume: 38 start-page: 229 year: 2011 ident: 10.1016/j.atherosclerosis.2016.07.897_bib55 article-title: Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis publication-title: J. Rheumatol. doi: 10.3899/jrheum.100582 – volume: 45 start-page: 1088 year: 2005 ident: 10.1016/j.atherosclerosis.2016.07.897_bib62 article-title: Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes publication-title: Hypertension doi: 10.1161/01.HYP.0000166722.91714.ba – volume: 50 start-page: 805 year: 2012 ident: 10.1016/j.atherosclerosis.2016.07.897_bib51 article-title: Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose publication-title: Int. J. Clin. Pharmacol. Ther. doi: 10.5414/CP201735 – volume: 114 start-page: 546 year: 2015 ident: 10.1016/j.atherosclerosis.2016.07.897_bib32 article-title: Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials publication-title: Thromb. Haemost. doi: 10.1160/TH14-11-0937 – volume: 16 start-page: 1 year: 2015 ident: 10.1016/j.atherosclerosis.2016.07.897_bib46 article-title: Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin publication-title: Atherosclerosis doi: 10.1016/S1567-5688(14)70002-9 – volume: 303 start-page: 82 year: 2002 ident: 10.1016/j.atherosclerosis.2016.07.897_bib39 article-title: Inhibition of glucose-and calcium-induced insulin secretion from βTC3 cells by novel inhibitors of protein isoprenylation publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.102.036160 – volume: 13 start-page: 229 year: 2015 ident: 10.1016/j.atherosclerosis.2016.07.897_bib20 article-title: Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies publication-title: BMC Med. doi: 10.1186/s12916-015-0459-4 – volume: 6 start-page: 772 year: 2006 ident: 10.1016/j.atherosclerosis.2016.07.897_bib1 article-title: Adipocytokines: mediators linking adipose tissue, inflammation and immunity publication-title: Nat. Rev. Immunol. doi: 10.1038/nri1937 – volume: 146 start-page: 319 year: 2011 ident: 10.1016/j.atherosclerosis.2016.07.897_bib65 article-title: Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension publication-title: Int. J. Cardiol. doi: 10.1016/j.ijcard.2009.07.002 – volume: 339 start-page: b2535 year: 2009 ident: 10.1016/j.atherosclerosis.2016.07.897_bib23 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: BMJ doi: 10.1136/bmj.b2535 – volume: 45 start-page: 1649 year: 2005 ident: 10.1016/j.atherosclerosis.2016.07.897_bib61 article-title: Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2005.02.052 – volume: 26 start-page: 501 year: 2012 ident: 10.1016/j.atherosclerosis.2016.07.897_bib54 article-title: The effect of HMG-CoA reductase inhibitor on insulin resistance in patients undergoing peritoneal dialysis publication-title: Cardiovasc. drugs Ther. doi: 10.1007/s10557-012-6412-2 – volume: 4 start-page: 279 year: 2010 ident: 10.1016/j.atherosclerosis.2016.07.897_bib56 article-title: Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087 publication-title: J. Clin. Lipidol. doi: 10.1016/j.jacl.2010.04.003 – volume: 37 start-page: 11 year: 2010 ident: 10.1016/j.atherosclerosis.2016.07.897_bib17 article-title: Adiponectin action from head to toe publication-title: Endocrine doi: 10.1007/s12020-009-9278-8 – volume: 68 start-page: 536 year: 2008 ident: 10.1016/j.atherosclerosis.2016.07.897_bib59 article-title: Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men publication-title: Clin. Endocrinol. doi: 10.1111/j.1365-2265.2007.03080.x – volume: 62 start-page: 3547 year: 2013 ident: 10.1016/j.atherosclerosis.2016.07.897_bib68 article-title: Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia publication-title: Diabetes doi: 10.2337/db13-0566 – volume: 227 start-page: 355 year: 2013 ident: 10.1016/j.atherosclerosis.2016.07.897_bib60 article-title: Effects of pravastatin on serum adiponectin levels in female patients with type 2 diabetes mellitus publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2013.01.045 – volume: 32 start-page: 181 year: 2015 ident: 10.1016/j.atherosclerosis.2016.07.897_bib19 article-title: Aerobic training increases the expression of adiponectin receptor genes in the peripheral blood mononuclear cells of young men publication-title: Biol. sport doi: 10.5604/20831862.1150298 – volume: 11 year: 2015 ident: 10.1016/j.atherosclerosis.2016.07.897_bib10 article-title: Epigenetics: obesity-induced hypermethylation of adiponectin gene, nature reviews publication-title: Endocrinology – volume: 32 start-page: 1924 year: 2009 ident: 10.1016/j.atherosclerosis.2016.07.897_bib35 article-title: Statin therapy and risk of developing type 2 diabetes: a meta-analysis publication-title: Diabetes care doi: 10.2337/dc09-0738 – volume: 13 start-page: 157 year: 2008 ident: 10.1016/j.atherosclerosis.2016.07.897_bib45 article-title: An overview of the extra-lipid effects of rosuvastatin publication-title: J. Cardiovasc Pharmacol. Ther. doi: 10.1177/1074248408318628 – reference: 27567030 - Atherosclerosis. 2016 Oct;253:270-272. doi: 10.1016/j.atherosclerosis.2016.08.009. |
| SSID | ssj0004718 |
| Score | 2.5730002 |
| SecondaryResourceType | review_article |
| Snippet | The effect of statin therapy on plasma adiponectin levels has not been conclusively studied. Therefore, we aimed to evaluate this effect through a systematic... Abstract Background and aims The effect of statin therapy on plasma adiponectin levels has not been conclusively studied. Therefore, we aimed to evaluate this... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 194 |
| SubjectTerms | Adiponectin Adiponectin - blood Adult Aged Atorvastatin - therapeutic use Cardiovascular Cardiovascular Diseases - blood Female Humans Hydroxymethylglutaryl-CoA reductase inhibitors Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Male Meta-analysis Middle Aged Pravastatin - therapeutic use Quinolines - therapeutic use Randomized Controlled Trials as Topic Regression Analysis Rosuvastatin Calcium - therapeutic use Simvastatin - therapeutic use Statins |
| Title | Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0021915016311984 https://www.clinicalkey.es/playcontent/1-s2.0-S0021915016311984 https://dx.doi.org/10.1016/j.atherosclerosis.2016.07.897 https://www.ncbi.nlm.nih.gov/pubmed/27498397 https://www.proquest.com/docview/1835359626 |
| Volume | 253 |
| WOSCitedRecordID | wos000389401200029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1879-1484 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004718 issn: 0021-9150 databaseCode: AIEXJ dateStart: 19950106 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELa6Dk18QbxTXiYjsU9TpiZO4hghRKmKGGgTEkP0m2UnDs3aJlXTTtP-An-LH8a5zkvbUdQh8SWKotq55J7enZ3n7hB6Zcd-JEgUWT51fQs8VGhJAYsVEUQ-CyNwMjJaNJugp6dBv8--NBq_ylyYixFN0-Dykk3-q6rhGihbp87eQN3VpHABzkHpcAS1w3ErxR9XeY86WcjQGHXhAP1ZYAKx8lgciiiZZKk2dZqEnhqC5kIik6i-Xt7ZsIbHaiYssVTExCWH4OmibJxcqagkvY_g1LQCEdOiEnpZ5FYLkuUgLhyTKpbvDqbzg653wN6DmTENlZNsVnGGv4qBkkNDA--Mk-kAvLpK6vw1NZZqaH2HoUl4NcxM_tEPTZNOK48DBlGajd4TAaJZXc06FMsbHrZfUefqBAQbbLSpV3vNA5jNiPMjsfpMmsS3KNMaGDrwauXtXvezbeXOUdvSH69tPTnEqbbNTPu6tYrcNs8d3ubXfrqDdh3qsaCJdjvHvf6nOj-X2iYiKATfQwc1z_Avgm6KlTathRYx0dlddKdYzOCOAeE91FDpfbR3UtA1HqCfBos4i7HBIi6wiLMUGyziJSziVSy-xh1cIxEbJGIAHF5Bop7dJbhGIq6RiBdIxBqJD9G3D72z7ker6P5hhb5DZxbxlafAV8tQkHZIlGOHEKv7ji10jTmXyjYjYE8UlZ4jwBJBrOvF7YjFNpFByALyCDVTkP8JwkxFVDmR6xEvdomQMKFkfigolTGE6KKF3pTvmYdFaXzdoWXESw7kOV9TE9dq4m3KQU0t5FfDJ6ZGzLYD35ZK5WUiNLhuDljedgL6pwlUXtijnG_Cagu9q0YWsbaJoW9y85clDjn4JP2hUaQqm8NNYVlHdFsvv4UeG4BWL8ahLuiG0af_LPozdLs2C89RczadqxfoVngxS_LpPtqh_WC_-Af-BqLTG4o |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+statin+therapy+on+plasma+adiponectin+concentrations%3A+A+systematic+review+and+meta-analysis+of+43+randomized+controlled+trial+arms&rft.jtitle=Atherosclerosis&rft.au=Chru%C5%9Bciel%2C+Piotr&rft.au=Sahebkar%2C+Amirhossein&rft.au=Rembek-Wieliczko%2C+Magdalena&rft.au=Serban%2C+Maria-Corina&rft.date=2016-10-01&rft.issn=0021-9150&rft_id=info:doi/10.1016%2Fj.atherosclerosis.2016.07.897&rft.externalDBID=ECK1-s2.0-S0021915016311984&rft.externalDocID=1_s2_0_S0021915016311984 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9150&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9150&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9150&client=summon |